New Delhi -°C
Today in New Delhi, India

Sep 23, 2020-Wednesday
-°C

Humidity
-

Wind
-

Select Country
Select city
ADVERTISEMENT
Home / World News / AstraZeneca in deal with Kangtai Bio to supply potential Covid-19 vaccine in China

AstraZeneca in deal with Kangtai Bio to supply potential Covid-19 vaccine in China

The two companies will also explore the possibility of cooperation on the vaccine candidate in other markets, AstraZeneca said.

world Updated: Aug 06, 2020 14:01 IST
Reuters| Posted by Susmita Pakrasi
Reuters| Posted by Susmita Pakrasi
Beijing
AstraZeneca PLC has signed an exclusive framework agreement with China’s Shenzhen Kangtai Biological Products to supply its Covid-19 vaccine candidate in mainland China
AstraZeneca PLC has signed an exclusive framework agreement with China’s Shenzhen Kangtai Biological Products to supply its Covid-19 vaccine candidate in mainland China(REUTERS)

AstraZeneca PLC has signed an exclusive framework agreement with China’s Shenzhen Kangtai Biological Products to supply its Covid-19 vaccine candidate in mainland China, the British pharmaceutical giant said on Thursday.

To meet market demand in China, Shenzhen Kangtai is obliged to make sure it has an annual production capacity of at least 100 million doses of the experimental shot AZD1222, which AstraZeneca co-developed with researchers at Oxford University, by the end of this year, and a capacity of at least 200 million doses by the end of next year, AstraZeneca said in a statement on the Chinese social media site WeChat.

The two companies will also explore the possibility of cooperation on the vaccine candidate in other markets, AstraZeneca said.

ht epaper

Sign In to continue reading